SECOS Group updates market on Malaysian property sale

|

Published 10-DEC-2018 10:00 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Sustainable and eco-friendly bioplastics developer SECOS Group Limited (ASX:SES) has released an update on the sale and leaseback of its Malaysian property, announced to the ASX in May.

Secos achieved a sale price of MYR 10.5 million (A$3.5 million) for the land and building. These proceeds will be used to reduce the company’s net debt of approximately A$1.3 million, with free cash of approximately A$2.2 million.

The Malaysian property is on a 99-year government freehold title, with the sale contract being subject to Malaysian government approval. The initial expected settlement date of November 2018 was therefore also subject to the timing of the approval process, which the company has now received.

SES’s Malaysian legal advisers have confirmed that the financial settlement and access to proceeds are now scheduled for 14 January 2019 or no later than 13 February 2019.

The small cap’s lawyers are now working with the buyer’s lawyers and its bank, CIMB, to discharge the collateral and sales proceeds in favour of SECOS.

The funds from the sale and leaseback will enable the company to accelerate its investment in resin manufacturing capacity to meet growing demand for its compostable bioplastic resins.

The company also recently completed a $2.1 million capital raising, consisting of a placement to sophisticated investors of $1.2 million and a Rights Issue to existing shareholders of $0.9 million. That funding will be used to provide cash flow for SES while it waits to receive the proceeds of the properly sale in early 2019.

In November, SES completed a strategic review into its wholly owned subsidiary Stellar Films Australia (SFA), the arm of the business which produces tradtional plastic films.

Through the review process, SES resolved to continue the transfer of SFA customers to its Malaysian operations and commence the cessation of its Australian film manufacturing operations — all to deliver some significant operating and overhead cost savings. Following these measures, the company is expecting its net profit after tax (NPAT) to improve by over $0.9 million a year.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X